8-K: Drugs Made In America II Appoints New CFO

Drugs Made In America Acquisition II Corp. announced the resignation of its CFO, Glenn Worman, and the appointment of Saleem Elmasri as his successor.

Summary

• Glenn Worman resigned as Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition II Corp., effective October 8, 2025.
• Mr. Worman stated that his resignation was not due to any disagreement with the Company's operations, policies, or practices.
• Saleem Elmasri was appointed as the new Chief Financial Officer and principal financial and accounting officer, effective November 17, 2025.
• Mr. Elmasri will provide his services through Titan Advisory Services LLC, for which the Company will pay $42,000 per year, or $3,500 per month.
• Additionally, Mr. Elmasri will receive 100,000 ordinary shares of the Company upon his engagement.
• Mr. Elmasri is a CPA with 20 years of experience in financial and management consulting, including prior roles at PricewaterhouseCoopers and leading advisory practices.

Sentiment

Score: 6

Explanation: The filing reports a routine executive transition with an experienced replacement, which is generally neutral to slightly positive. The amicable departure of the previous CFO and the strong background of the new CFO mitigate potential concerns.

Positives

• The appointment of Saleem Elmasri, an experienced CPA with 20 years in financial and management consulting, including Big-4 experience and a focus on the Life Sciences and Pharmaceutical industry, strengthens the Company's financial leadership.
• The outgoing CFO's resignation was amicable and not the result of any disagreements, suggesting a smooth transition.
• Mr. Elmasri's firm, Titan Advisory Services LLC, specializes in providing CFO services to early-stage companies, aligning with the needs of a Special Purpose Acquisition Company (SPAC).

Negatives

• The resignation of a principal financial and accounting officer, even if amicable, can sometimes introduce a period of adjustment for the company.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the effective date of the new CFO's appointment and the expectation of standard agreements being entered into.

Management Comments

• "Mr. Worman indicated that his resignation was not the result of any disagreement with the Company regarding its operations, policies, practices or otherwise."

Industry Context

This executive transition is a common occurrence for Special Purpose Acquisition Companies (SPACs) as they evolve, particularly as they prepare for or complete a business combination. The appointment of a financial professional with a strong background in life sciences and pharmaceuticals could be a strategic move for a SPAC focused on that sector.

Comparison to Industry Standards

• The compensation structure, which includes a consulting agreement with a firm and a share grant, is a common practice for early-stage companies or SPACs that may not initially have a full-time, in-house CFO.
• Mr. Elmasri's background, including experience at PricewaterhouseCoopers and with Fortune 500 clients in the Life Sciences and Pharmaceutical industry, represents strong credentials often sought by SPACs for their financial leadership.
• The grant of 100,000 ordinary shares aligns with typical equity incentives provided to key executives in growth-oriented companies, designed to align their interests with those of shareholders.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO could enhance financial oversight and strategic planning. The issuance of 100,000 shares to the new CFO represents a standard form of equity compensation, which involves some dilution but aligns executive incentives with shareholder interests.

Next Steps

• Saleem Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement, and a Registration Rights Agreement with the Company on the same terms as other directors and officers.

Key Dates

Recommendation

The filing details a standard executive transition for a SPAC, with an experienced CFO replacing the outgoing one. There are no significant positive or negative financial disclosures or strategic shifts that would warrant a change in investment stance based solely on this 8-K. The amicable nature of the departure and the qualifications of the new hire suggest business continuity.

Keywords

Drugs Made In America Acquisition II Corp, DMIIU, DMII, DMIIR, CFO appointment, executive change, financial officer, SPAC, corporate governance, Saleem Elmasri, Glenn Worman, Titan Advisory Services LLC